Methods for Using Aggregate Historical Control Data in Meta-Analyses of Clinical Trials With Time-to-Event Endpoints

被引:5
|
作者
Holzhauer, Bjorn [1 ]
机构
[1] Novartis Pharma AG, Biostat Sci & Pharmacometr, Basel, Switzerland
来源
关键词
Bayesian model averaging; Rare events; Robust meta-analytic predictive prior; Safety meta-analysis; Shrinkage priors; ANALYTIC-PREDICTIVE PRIORS; INFORMATION;
D O I
10.1080/19466315.2019.1610043
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
This article deals with comparing a test with a control therapy using meta-analyses of data from randomized controlled trials with a time-to-event endpoint. Such analyses can often benefit from prior information about the distribution of control group outcomes. One possible source of this information is the published aggregate data about control groups of historical trials from the medical literature. We review methods for making posterior inference about exponentially distributed event times more robust to prior-data conflicts by discounting the prior information based on the extent of observed prior-data conflict. We use simulations to compare analyses without prior information with the meta-analytic combined, meta-analytic predictive and robust meta-analytic predictive approaches, as well as Bayesian model averaging using shrinkage priors. Bayesian model averaging via shrinkage priors with well-chosen hyperpriors performed best in terms of credible interval coverage and mean-squared error across scenarios. For the robust meta-analytic predictive approach, there was little benefit in increasing the weight of the informative mixture components beyond 0.2-0.5. This was the case even when little prior-data conflict was expected, except with very sparse data or substantial between-trial heterogeneity in control group hazard rates. for this article are available online.
引用
收藏
页码:107 / 116
页数:10
相关论文
共 50 条
  • [11] Bayesian design of multi-regional clinical trials with time-to-event endpoints
    Bean, Nathan William
    Ibrahim, Joseph George
    Psioda, Matthew Austin
    BIOMETRICS, 2023, 79 (04) : 3586 - 3598
  • [12] Bayesian leveraging of historical control data for a clinical trial with time-to-event endpoint
    Roychoudhury, Satrajit
    Neuenschwander, Beat
    STATISTICS IN MEDICINE, 2020, 39 (07) : 984 - 995
  • [13] Exploring the characteristics, methods and reporting of systematic reviews with meta-analyses of time-to-event outcomes: a meta-epidemiological study
    Goldkuhle, Marius
    Hirsch, Caroline
    Iannizzi, Claire
    Zorger, Ana-Mihaela
    Bender, Ralf
    van Dalen, Elvira C.
    Hemkens, Lars G.
    Monsef, Ina
    Kreuzberger, Nina
    Skoetz, Nicole
    BMC MEDICAL RESEARCH METHODOLOGY, 2024, 24 (01)
  • [14] Meta-epidemiological review identified variable reporting and handling of time-to-event analyses in publications of trials included in meta-analyses of systematic reviews
    Goldkuhle, Marius
    Hirsch, Caroline
    Iannizzi, Claire
    Bora, Ana-Mihaela
    Bender, Ralf
    van Dalen, Elvira C.
    Hemkens, Lars G.
    Trivella, Marialene
    Monsef, Ina
    Kreuzberger, Nina
    Skoetz, Nicole
    JOURNAL OF CLINICAL EPIDEMIOLOGY, 2023, 159 : 174 - 189
  • [15] Assessing and improving the reliability of meta-analyses of hazard ratios derived from published time-to-event data
    Jayne Tierney
    David Fisher
    Sarah Burdett
    Lesley Stewart
    Mahesh Parmar
    Trials, 14 (Suppl 1)
  • [16] surrosurv: An R package for the evaluation of failure time surrogate endpoints in individual patient data meta-analyses of randomized clinical trials
    Rotolo, Federico
    Paoletti, Xavier
    Michiels, Stefan
    COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE, 2018, 155 : 189 - 198
  • [17] Evaluation of failure time surrogate endpoints in individual patient data meta-analyses of randomized clinical trials. A poisson approach
    Rotolo, Federico
    Paoletti, Xavier
    Burzykowski, Toasz
    Buyse, Marc
    Michiels, Stefan
    TRIALS, 2017, 18
  • [18] Protocol of the Definition for the Assessment of Time-to-event Endpoints in CANcer trials (DATECAN) project: Formal consensus method for the development of guidelines for standardised time-to-event endpoints' definitions in cancer clinical trials
    Bellera, Carine A.
    Pulido, Marina
    Gourgou, Sophie
    Collette, Laurence
    Doussau, Adelaide
    Kramar, Andrew
    Dabakuyo, Tienhan Sandrine
    Ouali, Monia
    Auperin, Anne
    Filleron, Thomas
    Fortpied, Catherine
    Le Tourneau, Christophe
    Paoletti, Xavier
    Mauer, Murielle
    Mathoulin-Pelissier, Simone
    Bonnetain, Franck
    EUROPEAN JOURNAL OF CANCER, 2013, 49 (04) : 769 - 781
  • [19] An evaluation of statistical methods for predicting timelines for reaching target number of events in clinical trials with time-to-event endpoints
    Clark, Emma
    Helms, Hans-Joachim
    Stanzel, Sven
    Xia, Fan
    TRIALS, 2017, 18
  • [20] Imputation of Missing Data for Time-to-Event Endpoints Using Retrieved Dropouts
    Shuai Wang
    Robert Frederich
    James P. Mancuso
    Therapeutic Innovation & Regulatory Science, 2024, 58 : 114 - 126